Pharmacia Italia S.p.a.

Other

Pfizer Corporation

Pharmacia Ab

Farmitalia Carlo Erba S.r.l.

Nerviano Medical Sciences S.r.l.

Pharmacia S.p.a.

Alessandro Martini

Lorena Muggetti

Roberto De Ponti

Paola Civaroli

Giovanni Buzzi

Sara Lauria

Cristina Ciocca

Giuseppe Colombo

Carlo Confalonieri

Maria Cristina Geroni

Paolo Colombo

Giuseppe Maccari

Christopher James

Paolo Elia Cappella

Olga Valota

Lloyd E Fox

Clara Torricelli

Federico Federici

Benito Argenti

The present invention relates to pharmaceutical composition containing nemorubicin hydrochloride incorporated in microspheres. The compositions are useful for chemoembolization, particularly for loco regional treatment of tumors.

Pharmaceutical composition of an anthracycline

The present invention relates to a semi-solid filling medium which comprises a camptothecin derivative; a pharmaceutically acceptable carrier matrix which is a polyglycolized glyceride; and an effective thickening-reducing and stabilizing-promoting amount of one or more pharmaceutically acceptable excipients.

Oral formulations for anti-tumor compounds

A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustin phosphate to be administered with no side effects at the site of injection.

Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

The present invention relates to novel stable solution formulations comprising oxaliplatin alone or in combination with irinotecan (CPT-11), an effective stabilizing amount of lactic acid and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method for manufacturing such formulations ready for administration and their use in the antitumor therapy are also within the scope of the invention.

Platinum derivative pharmaceutical formulations

An oral pharmaceutical formulation, which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethyleneglycol with a molecular weight ranging from 400 to 20000.

Pharmaceutical formulations in hydroxypropylmethylcellulose capsules

Stabilized aqueous suspensions for parenteral use

The present invention relates to novel stable solution formulations comprising oxaliplatin, an effective stabilizing amount of lactic acid and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method for manufacturing such formulations ready for administration and their use in the antitumor therapy are also within the scope of the invention.

Bioadhesive starches and process for their preparation

Estramustine formulations with improved pharmaceutical properties

A pharmaceutical composition comprising a drug and a dehydrated cyclodextrin having improved dissolution properties, and the process for the preparation thereof.

Pharmaceutical compositions having improved dissolution properties

A novel milk coagulating enzyme is produced by cultivating a yeast of the group Cryptococcus albidus and its variants aerius and diffluens on a culture medium containing assimilable carbon, nitrogen and trace nutrients at a temperature between 15.degree. C. and 40.degree. C. under aerobic conditions, and at a pH of between 3.0 and 8.0. The enzyme is recovered from the culture medium, for example, by salting-out, dialyzed and freeze-dried. The preparations obtained are characterized by high milk-clotting activity with very low proteolytic activity.

Milk coagulating microbial enzyme

Growing community of inventors

Milan, Italy

Alessandro Martini